- Company
- 'Lorviqua' accepts DREC condition…negotiations to start
- by Eo, Yun-Ho Feb 11, 2025 06:02am
- The final review process is about to begin for expanded reimbursement of the non-small cell lunger cancer treatment 'Lorviqua' as a first-line treatment. According to industry sources, Pfizer Korea accepted the condition of 'accepting the drug price below the evaluated amount' suggested by the Drug Reimbursement Evaluation Committee (DREC
- Company
- Mitsubishi Tanabe Pharma sold to private equity fund
- by Whang, byung-woo Feb 11, 2025 06:02am
- The sale of Japanese pharmaceutical company Mitsubishi Tanabe Pharma to a global private equity firm is expected to bring changes to its Korean branch as well. Although the company is being sold, it is not being sold by business unit, so its effect on the overall market is expected to be small. Rather, the sales are expected to increase suppo
- Policy
- KAPO ‘CDDC should pass Keytruda’s reimb extension agenda’
- by Lee, Tak-Sun Feb 11, 2025 06:02am
- A patient group has called for the immediate expansion of the coverage of the immuno-oncology drug 'Keytruda'. With the National Health Insurance Service's Cancer Disease Deliberation Committee scheduled to meet on the 12th, the group is asking for the establishment of reimbursement standards to strengthen patient access to treatment. In
- Opinion
- [Reporter’s View] Trodelvy makes way to reimb in KOR
- by Eo, Yun-Ho Feb 10, 2025 05:51am
- The wait was worth it. The triple-negative breast cancer (TNBC) treatment Trodelvy (sacituzumab govitecan-hziy) has passed the Drug Reimbursement Evaluation Committee review, nearly 15 months after passing the Health Insurance Review and Assessment Service’s Cancer Disease Review Committee review. The most promising aspect of the news
- Company
- OliX licenses out RNA-based MASH drug technology to Lilly
- by Feb 10, 2025 05:50am
- OliX, a company developing RNA-based new drugs, has transferred its metabolic dysfunction-associated steatohepatitis (MASH) and obesity drug candidate to the multinational pharmaceutical company Eli Lilly. On the 7th, OliX announced that it had signed a joint development and technology export agreement with Lilly for its MASH and obesity
- Company
- Bayer Korea marks 70th year, preparing for 100-yr milestone
- by Whang, byung-woo Feb 10, 2025 05:50am
- Bayer Korea, celebrating its 70th year in business in the Korean market, is preparing for the next leap toward the 100th year. The company plans to enhance the capacity of treatments already launched in the market and its new growth driver pipeline, aiming for long-term and continuous business growth. Additionally, as the importance of th
- Company
- New TED drug 'Tepezza' under review for marketing approval
- by Eo, Yun-Ho Feb 10, 2025 05:50am
- The commercialization of 'Tepezza,' a targeted treatment for Thyroid Eye Disease, is expected. According to industry sources, the Ministry of Food and Drug Safety (MFDS) is reviewing the approval of the Thyroid Eye Disease (TED) treatment, Tepezza (teprotumumab). This drug was designated as an orphan drug in South Korea in August 2024.
- Policy
- Pricing negotiations complete for Pfizer’s Vyndamax
- by Lee, Tak-Sun Feb 10, 2025 05:50am
- Pfizer has completed pricing negotiations with the National Health Insurance Service for its cardiomyopathy drug, Vyndamax Cap (tafamidis). As a result, the drug is soon expected to be listed for reimbursement benefits in Korea. Four and a half years after its approval in August 2020, the drug is finally being included in Korea’s health
- Company
- Will Keytruda’s reimbursement standards be set this time?
- by Whang, byung-woo Feb 7, 2025 05:52am
- Keytruda, for which MSD had submitted reimbursement applications to extend its coverage to 17 indications, is gaining industry attention as it is expected to be presented to the Cancer Disease Deliberation Committee for the first time this year. According to industry sources, MSD Korea's Keytruda (pembrolizumab) will be presented to the K
- Company
- Will the non-reimb status of 'Padcev' change this year?
- by Eo, Yun-Ho Feb 7, 2025 05:51am
- The industry is paying attention to the progress of reimbursing monotherapy·combination therapy of 'Padcev,' the new ADC drug for bladder cancer. Astellas Korea's Antibody-Drug Conjugates (ADC) Padcev (enfortumab) is expected to be considered for the Cancer Disease Review Committee of the Health Insurance Review and Assessment Service (HI
